These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 18765824)

  • 21. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2.
    Mizuarai S; Aozasa N; Kotani H
    Int J Cancer; 2004 Mar; 109(2):238-46. PubMed ID: 14750175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates.
    Bram E; Ifergan I; Shafran A; Berman B; Jansen G; Assaraf YG
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):826-34. PubMed ID: 16612649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human multidrug transporter ABCG2, a target for sensitizing drug resistance in cancer chemotherapy.
    Xu J; Peng H; Zhang JT
    Curr Med Chem; 2007; 14(6):689-701. PubMed ID: 17346156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase.
    Ji N; Yuan J; Liu J; Tian S
    Acta Biochim Biophys Sin (Shanghai); 2010 Dec; 42(12):854-62. PubMed ID: 21106767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).
    Kort A; Durmus S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Pharm Res; 2015 Jul; 32(7):2205-16. PubMed ID: 25563977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
    Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
    Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ABCG2 confers resistance to indolocarbazole compounds by ATP-dependent transport.
    Nakagawa R; Hara Y; Arakawa H; Nishimura S; Komatani H
    Biochem Biophys Res Commun; 2002 Dec; 299(4):669-75. PubMed ID: 12459192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution.
    Takenaka K; Morgan JA; Scheffer GL; Adachi M; Stewart CF; Sun D; Leggas M; Ejendal KF; Hrycyna CA; Schuetz JD
    Cancer Res; 2007 Jul; 67(14):6965-72. PubMed ID: 17638908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phorbol ester TPA modulates chemoresistance in the drug sensitive breast cancer cell line MCF-7 by inducing expression of drug efflux transporter ABCG2.
    Kalalinia F; Elahian F; Hassani M; Kasaeeian J; Behravan J
    Asian Pac J Cancer Prev; 2012; 13(6):2979-84. PubMed ID: 22938493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-speed screening and quantitative SAR analysis of human ABC transporter ABCG2 for molecular modeling of anticancer drugs to circumvent multidrug resistance.
    Saito H; Hirano H; Ishikawa T
    Mini Rev Med Chem; 2007 Oct; 7(10):1009-18. PubMed ID: 17979803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitro.
    Cihalova D; Ceckova M; Kucera R; Klimes J; Staud F
    Biochem Pharmacol; 2015 Dec; 98(3):465-72. PubMed ID: 26300056
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
    Sun YL; Kathawala RJ; Singh S; Zheng K; Talele TT; Jiang WQ; Chen ZS
    Anticancer Drugs; 2012 Sep; 23(8):865-73. PubMed ID: 22614107
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin.
    Chearwae W; Shukla S; Limtrakul P; Ambudkar SV
    Mol Cancer Ther; 2006 Aug; 5(8):1995-2006. PubMed ID: 16928820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hedgehog signaling regulates drug sensitivity by targeting ABC transporters ABCB1 and ABCG2 in epithelial ovarian cancer.
    Chen Y; Bieber MM; Teng NN
    Mol Carcinog; 2014 Aug; 53(8):625-34. PubMed ID: 23423781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interleukin-1 beta and tumor necrosis factor-alpha increase ABCG2 expression in MCF-7 breast carcinoma cell line and its mitoxantrone-resistant derivative, MCF-7/MX.
    Mosaffa F; Lage H; Afshari JT; Behravan J
    Inflamm Res; 2009 Oct; 58(10):669-76. PubMed ID: 19333723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A 96-well efflux assay to identify ABCG2 substrates using a stably transfected MDCK II cell line.
    Xiao Y; Davidson R; Smith A; Pereira D; Zhao S; Soglia J; Gebhard D; de Morais S; Duignan DB
    Mol Pharm; 2006; 3(1):45-54. PubMed ID: 16686368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation between adenosine triphosphate (ATP)-binding cassette transporter G2 (ABCG2) and drug resistance of esophageal cancer and reversal of drug resistance by artesunate.
    Wang L; Liu L; Chen Y; Du Y; Wang J; Liu J
    Pathol Res Pract; 2018 Sep; 214(9):1467-1473. PubMed ID: 30104076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overcoming ABCG2-mediated drug resistance with imidazo-[1,2-b]-pyridazine-based Pim1 kinase inhibitors.
    Darby RA; Unsworth A; Knapp S; Kerr ID; Callaghan R
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):853-64. PubMed ID: 26351135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
    Ji N; Yang Y; Lei ZN; Cai CY; Wang JQ; Gupta P; Xian X; Yang DH; Kong D; Chen ZS
    Biochem Pharmacol; 2018 Dec; 158():274-285. PubMed ID: 30431011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.